86 related articles for article (PubMed ID: 15927092)
21. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
[TBL] [Abstract][Full Text] [Related]
22. Short-term prospective comparison of prepulse inhibition between schizophrenic patients and healthy controls.
Preuss UW; Zimmermann J; Watzke S; Langosch J; Siafarikas N; Wong JW; Hamm A; Weike A
Pharmacopsychiatry; 2011 May; 44(3):102-8. PubMed ID: 21432751
[TBL] [Abstract][Full Text] [Related]
23. Effects of clozapine on cognitive function in schizophrenia.
Lee MA; Thompson PA; Meltzer HY
J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
[TBL] [Abstract][Full Text] [Related]
24. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
Szulc A; Galińska B; Tarasów E; Kubas B; Dzienis W; Konarzewska B; Poplawska R; Tomczak AA; Czernikiewicz A; Walecki J
Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
26. Brain potential evidence for an auditory sensory memory deficit in schizophrenia.
Catts SV; Shelley AM; Ward PB; Liebert B; McConaghy N; Andrews S; Michie PT
Am J Psychiatry; 1995 Feb; 152(2):213-9. PubMed ID: 7840354
[TBL] [Abstract][Full Text] [Related]
27. Effects of typical, atypical, and no antipsychotic drugs on visual contrast detection in schizophrenia.
Chen Y; Levy DL; Sheremata S; Nakayama K; Matthysse S; Holzman PS
Am J Psychiatry; 2003 Oct; 160(10):1795-801. PubMed ID: 14514493
[TBL] [Abstract][Full Text] [Related]
28. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
29. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia.
Gur RE; Maany V; Mozley PD; Swanson C; Bilker W; Gur RC
Am J Psychiatry; 1998 Dec; 155(12):1711-7. PubMed ID: 9842780
[TBL] [Abstract][Full Text] [Related]
30. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics.
Xiu MH; Hui L; Dang YF; Hou TD; Zhang CX; Zheng YL; Chen DC; Kosten TR; Zhang XY
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1508-12. PubMed ID: 19720106
[TBL] [Abstract][Full Text] [Related]
31. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
32. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV
CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250
[TBL] [Abstract][Full Text] [Related]
33. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
Strzelecki D; Rabe-Jabłońska J
Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
[TBL] [Abstract][Full Text] [Related]
34. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study.
Yildiz M; Cerit C
Int J Psychiatry Clin Pract; 2004; 8(1):41-5. PubMed ID: 24937582
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
[TBL] [Abstract][Full Text] [Related]
37. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
[TBL] [Abstract][Full Text] [Related]
38. Effects of atypical neuroleptics on alertness and visual orienting in stabilized schizophrenic patients: a preliminary study.
Daban C; Krebs MO; Bourdel MC; Willard D; Loo H; Olié JP; Poirier MF; Amado I
Int J Neuropsychopharmacol; 2004 Sep; 7(3):255-63. PubMed ID: 15050039
[TBL] [Abstract][Full Text] [Related]
39. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
Nagase Y; Okubo Y; Toru M
Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals.
Barkan T; Peled A; Modai I; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2006 Aug; 16(6):429-36. PubMed ID: 16431091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
